Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Published:2019-11 Issue:11 Volume:7 Page:834-844
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Lingvay Ildiko,Catarig Andrei-Mircea,Frias Juan P,Kumar Harish,Lausvig Nanna L,le Roux Carel W,Thielke Desirée,Viljoen Adie,McCrimmon Rory J

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference31 articles.

1. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary;Garber;Endocr Pract,2019

2. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes 2019;Diabetes Care,2019

3. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Davies;Diabetes Care,2018

4. The cardiovascular biology of glucagon-like peptide-1;Drucker;Cell Metab,2016

5. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review;Verma;Diabetologia,2018

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review;Cureus;2024-09-01

2. Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme;Diabetes, Obesity and Metabolism;2024-08-08

3. Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus;Pharmacia;2024-08-02

4. New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease;Diagnostics;2024-07-10

5. Intranasal delivery of glucagon-like peptide-1 to the brain for obesity treatment: opportunities and challenges;Expert Opinion on Drug Delivery;2024-07-02